However, DNMT inhibitors can be used to treat a variety of hematological tumors, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) [15–17]. This evidence concerns the gene DNMT1 and chronic myelogenous leukemia, BCR-ABL1 positive.